IPO activity in 2025 showed a marked rebound, led by the technology and healthcare sectors, after last year's sluggish performance. Aktis Oncology,
Everything you need to know about Aktis Oncology’s upcoming IPO
Categories
pharmaceuticals
Micron Q1 2026 earnings beat estimates; revenue surges 57%
Memory chipmaker Micron Technology Inc. (NASDAQ: MU) on Wednesday reported stronger-than-expected earnings for the first quarter of fiscal 2026. Revenue increased 57%
Pfizer affirms FY25 earnings guidance, provides full-year 2026 outlook
Pfizer Inc. (NYSE: PFE) has reaffirmed its earnings outlook for fiscal 2025 and revised revenue guidance. The pharma giant also initiated guidance
Unicycive is all-in on kidney care, focusing on underserved areas: CEO
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a biotech firm engaged in the development of novel treatment options for patients with renal diseases.
Earnings Summary: CooperCompanies reports higher Q4 revenue, adj. profit
CooperCompanies (NYSE: COO) has reported an increase in revenues and adjusted earnings for the fourth quarter of fiscal 2025. The medical device
Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies
Viatris (VTRS) posts Q3 2025 results and updates 2025 guidance
Pharmaceuticals company Viatris Inc. (NASDAQ: VTRS) on Thursday reported financial results for the third quarter of fiscal 2025, and updated its outlook
Earnings Summary: Humana Q3 2025 profit drops despite higher revenues
Humana Inc. (NYSE: HUM), a leading health and well-being company, on Wednesday reported a decline in adjusted earnings for the third quarter
Key takeaways from Pfizer’s (PFE) Q3 2025 earnings report
Shares of Pfizer Inc. (NYSE: PFE) stayed green during midday trade on Tuesday following the company’s announcement of its third quarter 2025
PFE Earnings: All you need to know about Pfizer’s Q3 2025 earnings results
Pfizer Inc. (NYSE: PFE) reported its third quarter 2025 earnings results today. Revenues were $16.7 billion, down 6% on a reported basis
ABBV Earnings: A snapshot of AbbVie’s Q3 2025 report
Pharmaceuticals company AbbVie, Inc. (NYSE: ABBV) on Friday reported a decline in earnings for the third quarter of fiscal 2025, despite an
BIIB Earnings: A snapshot of Biogen’s Q3 2025 results
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported an increase in adjusted profit for the third quarter of 2025 when its revenues remained
Earnings Summary: Cardinal Health Q1 2026 revenue jumps 22%; raises guidance
Pharmaceuticals distributor Cardinal Health (NYSE: CAH) reported a sharp increase in revenue and adjusted earnings for the first quarter of fiscal 2026.
Bristol Myers Squibb (BMY) Earnings: 3Q25 Key Numbers
Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2025 earnings results today. Revenues increased 3% year-over-year to $12.2 billion. GAAP net
Eli Lilly (LLY) Earnings: 3Q25 Key Numbers
Eli Lilly and Company (NYSE: LLY) reported its third quarter 2025 earnings results today. Worldwide revenue was $17.60 billion, up 54% from
Key highlights from Merck’s (MRK) Q3 2025 earnings results
Merck & Co., Inc. (NYSE: MRK) reported its third quarter 2025 earnings results today. Total worldwide sales of $17.3 billion were up
UnitedHealth Group’s Q3 2025 earnings fall despite double-digit revenue growth
Healthcare behemoth UnitedHealth Group (NYSE: UNH) announced results for the third quarter of fiscal 2025, reporting an increase in revenues and a
Abbott Laboratories Q3 adj. earnings rise on higher sales; meet Street view
Abbott Laboratories (NYSE: ABT) reported higher sales and adjusted earnings for the third quarter of fiscal 2025. The healthcare company also reaffirmed
Kairos Pharma’s goal is to intervene early in resistance and re-sensitize cancer cells to therapy: CEO
Kairos Pharma, Ltd. (NYSE: KAPA) is a biopharma company developing a pipeline of targeted therapies for cancer patients with high unmet medical
JNJ Earnings: Key quarterly highlights from Johnson & Johnson’s Q3 2025 financial results
Johnson & Johnson (NYSE: JNJ) reported its third quarter 2025 earnings results today. Reported sales increased 6.8% year-over-year to $24 billion. Operational
IPO News: MapLight Therapeutics targets $704 mln valuation in Nasdaq debut
In recent months, Wall Street has seen a surge of healthcare firms seeking to go public, as IPO activity continues to regain